Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
95 studies found for:    hedgehog
Show Display Options
Rank Status Study
1 Recruiting Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
Conditions: Histologically Confirmed Medulloblastoma;   Activation of the Sonic Hedgehog (SHH) Pathway
Interventions: Drug: vismodegib;   Drug: Temozolomide
2 Completed
Has Results
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Vismodegib 150 mg;   Drug: Placebo to vismodegib;   Drug: Bevacizumab;   Drug: Modified FOLFOX;   Drug: FOLFIRI
3 Active, not recruiting
Has Results
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
Conditions: Extensive Stage Small Cell Lung Carcinoma;   Recurrent Small Cell Lung Carcinoma
Interventions: Drug: Cisplatin;   Biological: Cixutumumab;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Vismodegib
4 Active, not recruiting Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Condition: Metastatic Pancreatic Cancer
Intervention: Drug: Gemcitabine, nab-Paclitaxel, GDC-0449
5 Recruiting LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
Conditions: Hepatocellular Carcinoma;   Cirrhosis
Intervention: Drug: LDE225
6 Terminated Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)
Condition: Pancreatic Ductal Adenocarcinoma
Intervention: Drug: GDC-0449
7 Unknown  Preliminary Study of Sonic Hedgehog Signaling Pathway in the Pathogenesis of Rheumatoid Arthritis
Conditions: Arthritis, Rheumatoid;   Neovascularization, Pathologic;   Synovitis
8 Recruiting Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients
Condition: Esophageal Cancer
Intervention: Drug: Itraconazole
9 Completed A Study Of PF-04449913 Administered Alone In Select Solid Tumors
Condition: Solid Tumors
Intervention: Drug: PF-04449913
10 Recruiting Interrogation of Wnt, Notch and Hedgehog Activity in Primary Tumor Samples
Condition: Cancer
11 Completed
Has Results
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Conditions: Medulloblastoma,;   Rhabdomyosarcoma,;   Neuroblastoma,;   Hepatoblastoma,;   Glioma,;   Astrocytoma
Intervention: Drug: LDE225
12 Completed
Has Results
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Condition: Solid Cancers
Intervention: Drug: GDC-0449
13 Withdrawn A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer
Condition: Pancreatic Ductal Adenocarcinoma
Intervention: Drug: LDE225
14 Completed
Has Results
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
Condition: Ovarian Cancer
Interventions: Drug: Vismodegib 150 mg;   Drug: Placebo to vismodegib
15 Recruiting PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia
Intervention: Drug: Hedgehog inhibitor PF-04449913
16 Active, not recruiting Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Condition: Resectable Pancreatic Adenocarcinoma
Interventions: Drug: LDE-225;   Drug: Gemcitabine;   Drug: nab-paclitaxel
17 Recruiting A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Condition: Acute Myeloid Leukemia
Interventions: Drug: PF-04449913;   Drug: Low dose ARA-C (LDAC);   Drug: Decitabine;   Drug: Daunorubicin;   Drug: Cytarabine
18 Not yet recruiting Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer
Condition: Pancreatic Adenocarcinoma Resectable
Interventions: Drug: gemcitabine;   Drug: Vismodegib;   Procedure: Neoadjuvant chemotherapy
19 Completed To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)
Conditions: Basal Cell Nevus Syndrome;   Gorlin Syndrome
Intervention: Drug: GDC-0449
20 Completed A Study Of PF-04449913 In Select Hematologic Malignancies
Condition: Hematologic Malignancies
Intervention: Drug: PF-04449913

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years